Lead Product(s): NT-0167
Therapeutic Area: Immunology Product Name: Undisclosed
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Novo Holdings
Deal Size: $55.0 million Upfront Cash: Undisclosed
Deal Type: Series B Financing June 03, 2020
Proceeds to support advancement of pipeline of small molecule NLRP3 inflammasome inhibitors, including continued progression of NT-0167 through clinical development.